JP2007512335A5 - - Google Patents

Download PDF

Info

Publication number
JP2007512335A5
JP2007512335A5 JP2006541295A JP2006541295A JP2007512335A5 JP 2007512335 A5 JP2007512335 A5 JP 2007512335A5 JP 2006541295 A JP2006541295 A JP 2006541295A JP 2006541295 A JP2006541295 A JP 2006541295A JP 2007512335 A5 JP2007512335 A5 JP 2007512335A5
Authority
JP
Japan
Prior art keywords
formula
compound
ethyl
propyl
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006541295A
Other languages
English (en)
Japanese (ja)
Other versions
JP4769728B2 (ja
JP2007512335A (ja
Filing date
Publication date
Priority claimed from US10/719,102 external-priority patent/US7125993B2/en
Application filed filed Critical
Publication of JP2007512335A publication Critical patent/JP2007512335A/ja
Publication of JP2007512335A5 publication Critical patent/JP2007512335A5/ja
Application granted granted Critical
Publication of JP4769728B2 publication Critical patent/JP4769728B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006541295A 2003-11-21 2004-11-15 A2bアデノシンレセプターアンタゴニスト Expired - Fee Related JP4769728B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/719,102 US7125993B2 (en) 2001-11-09 2003-11-21 A2B adenosine receptor antagonists
US10/719,102 2003-11-21
PCT/US2004/038136 WO2005051951A1 (en) 2003-11-21 2004-11-15 A2b adenosine receptor antagonists

Publications (3)

Publication Number Publication Date
JP2007512335A JP2007512335A (ja) 2007-05-17
JP2007512335A5 true JP2007512335A5 (https=) 2007-12-13
JP4769728B2 JP4769728B2 (ja) 2011-09-07

Family

ID=34633233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541295A Expired - Fee Related JP4769728B2 (ja) 2003-11-21 2004-11-15 A2bアデノシンレセプターアンタゴニスト

Country Status (15)

Country Link
US (3) US7125993B2 (https=)
EP (1) EP1685132B1 (https=)
JP (1) JP4769728B2 (https=)
KR (1) KR101140186B1 (https=)
CN (1) CN100415748C (https=)
AU (1) AU2004292529B2 (https=)
CA (1) CA2546733C (https=)
ES (1) ES2391178T3 (https=)
IL (1) IL175759A0 (https=)
MX (1) MXPA06005637A (https=)
NZ (1) NZ547357A (https=)
RU (1) RU2374247C2 (https=)
TW (1) TWI365879B (https=)
WO (1) WO2005051951A1 (https=)
ZA (1) ZA200604046B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
CA2671940A1 (en) * 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
WO2003063800A2 (en) * 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
NZ537975A (en) * 2002-07-29 2007-08-31 Cv Therapeutics Inc Method of producing coronary vasodilation without peripheral vasodilation comprising administering at least 10 mcg of at least one A2A receptor agonist
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
EP1799221A1 (en) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
KR20070083714A (ko) 2004-10-20 2007-08-24 씨브이 쎄러퓨틱스, 인코포레이티드 A2a 아데노신 수용체 작용제의 용도
NZ564326A (en) * 2005-06-16 2010-01-29 Cv Therapeutics Inc Prodrugs of A2B adenosine receptor antagonists
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) * 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
US7732595B2 (en) 2006-02-03 2010-06-08 Gilead Palo Alto, Inc. Process for preparing an A2A-adenosine receptor agonist and its polymorphs
WO2007109547A2 (en) * 2006-03-17 2007-09-27 Cv Therapeutics, Inc. Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
RU2459626C2 (ru) * 2006-09-01 2012-08-27 Гайлид Сайэнсиз, Инк. Способы и композиции, повышающие переносимость пациентом методов визуализации миокарда
US20080170990A1 (en) * 2006-09-29 2008-07-17 Cv Therapeutics, Inc. Methods for Myocardial Imaging in Patients Having a History of Pulmonary Disease
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
JP2010515081A (ja) * 2007-01-03 2010-05-06 ギリアード・パロ・アルト・インコーポレイテッド 心筋灌流画像化
US20110118276A1 (en) * 2008-07-16 2011-05-19 Edward Leung Methods of treating atherosclerosis
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
US20120003329A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
MX2020009286A (es) 2018-03-05 2020-12-11 Teon Therapeutics Inc Antagonistas del receptor de adenosina y usos de los mismos.
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
CN116322698A (zh) * 2020-09-04 2023-06-23 泰昂治疗公司 腺苷a2b受体拮抗剂的共晶

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4539707A (en) * 1982-06-01 1985-09-03 Aerotron, Inc. Compressed single side band communications system and method
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE8817122U1 (de) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Xanthinderivate mit Adenosinantogenistischer Wirkung
IT1229195B (it) 1989-03-10 1991-07-25 Poli Ind Chimica Spa Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
TW252044B (https=) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
GB9703044D0 (en) * 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6117878A (en) 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
ATE234099T1 (de) 1998-04-24 2003-03-15 Leuven K U Res & Dev Immununterdrückende effekte von 8 substituierten xanthinderivaten
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
ES2273487T3 (es) 1998-06-01 2007-05-01 Astellas Pharma Inc. Antagonistas a1 de adenosina contra la esterilidad masculina.
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
ATE520694T1 (de) * 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists

Similar Documents

Publication Publication Date Title
JP2007512335A5 (https=)
RU2006117349A (ru) Антагонисты аденозиновых рецепторов а2в
CN1070489C (zh) 取代的亚砜类化合物的合成方法
JP6488359B2 (ja) ベンズイミダゾール誘導体の製造方法
US6255491B1 (en) Synthesis of intermediate compounds for 4-adyl-5-pyrimidine imidazole substituted derivatives
JP6367556B2 (ja) ピラゾール−4−カルボキサミドの製造方法
JP2012502097A (ja) アミノスルホン化合物を調製するためのプロセス
JP2009533369A5 (https=)
JP2005529954A5 (https=)
TWI283667B (en) Selective synthesis of CF3-substituted pyrimidines
JP2007536231A5 (https=)
US20230312545A1 (en) Process For Preparing Aminopyrimidine Derivatives
TWI430999B (zh) 有機化合物之合成方法
KR101058284B1 (ko) 2-(2-n-부틸-4-히드록시-6-메틸-피리미딘-5-일)-N,N-디메틸아세트아미드의 신규한 제조방법
JP2009504800A5 (https=)
CN1533378A (zh) 制备喹唑啉的方法
CN117203200A (zh) 黄嘌呤氧化酶抑制剂的制备方法
CN1606557A (zh) 经氘代的吡唑嘧啶酮以及包含该化合物的药物组合物
CN1117746C (zh) 制备取代的吡啶类化合物的方法及由该方法获得的吡啶类化合物
RU2012132277A (ru) Способ получения индазол-3-карбоновой кислоты и гидрохлорида n-(s)-1-азабицикло(2.2.2)окт-3-ил-1н-индазол-3-карбоксамида
CN1487916A (zh) 方法
CN1466571A (zh) 制备△1-吡咯啉的方法
US6239279B1 (en) Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
CN1774436A (zh) 5-氯-1-芳基-4-(4,5-二氰基-1h-咪唑-2-基)-3-烷基-1h-吡唑衍生物的合成方法
JPH10231298A (ja) ヘキサヒドロチエノ[3,4−d]イミダゾール−2,4−ジオン類の製造法